The following is a summary of the Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Quoin Pharmaceuticals Ltd ended the year with around $10.7 million cash and marketable securities, in comparison to $14 million at the end of Q3.

• Net loss for the year was reported to be $8.7 million, which is a decrease from the $9.4 million recorded in 2022, mainly due to increase in interest income, lower professional fees, and decreased G&A costs. This was partially offset by the upward trend in R&D spending.

Business Progress:

• QNRX has achieved significant progress in clinical trials for Netherton syndrome, receiving the first-ever clinical data from its open IND with the US FDA, providing encouraging and positive results on multiple clinical endpoints.

• Quoin successfully submitted several amendments to increase the size of its studies, change the dosing frequency, and reduce eligibility age.

• 2024 is expected to be a pivotal year for Quoin Pharmaceuticals, as they plan to roll out the first FDA approved treatment for Netherton syndrome.

• The company is establishing its own infrastructure to sell their product in the US and Western Europe post approval and has entered into nine commercial partnerships covering 61 entities.

• Quoin is also focusing on potential M&A activities as part of their future growth strategy while maintaining a robust balance sheet.

More details: Quoin Pharmaceuticals IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.